At a glance
ClinicalIndex Comparison Record- ✓Age 18 to 55 years
- ✓Body mass index greater than 35 kg/m²
- ✓Prescribed levofloxacin but not yet administered (hospitalized patients only)
- ✕Hypersensitivity or allergy to fluoroquinolones
- ✕Creatinine clearance less than 50 mL/min
- ✕Levofloxacin administration within previous 7 days
- ✕Pregnant or lactating females
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Levofloxacin Pharmacokinetics in the Severely Obese
In Brief
A Phase 4 clinical trial evaluating Levofloxacin 750 mg IV for Obesity and Critical Illness. Completed, enrolled 15 participants across 1 site.
Detailed Summary
Obesity is known to affect the concentrations of certain medications in the body. Levofloxacin is a commonly used antibiotic. Based on what the investigators know about levofloxacin and how it moves through the body, obesity may affect levofloxacin concentrations. This study aims to show the effect of obesity on levofloxacin concentrations. The hypothesis is as follows: A 750 mg intravenous (IV) dose of levofloxacin administered to severely obese, critically ill patients will yield serum concentrations that are likely to be therapeutic.
Study Details
Timeline
Interventions
PK in obesity